Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer

Published:2022-08-02 Issue:6 Volume:5 Page:442-445
ISSN:2577-171X
Container-title:IJU Case Reports
language:en
Short-container-title:IJU Case Reports

Author:

Kageyama Takumi¹²³^ORCID,Soga Norihito²^ORCID,Sekito Sho²^ORCID,Kato Seiichi⁴^ORCID,Ogura Yuji²,Kojima Takahiro²,Kanai Masahiro³,Inoue Takahiro¹^ORCID

Affiliation:

1. Department of Nephro‐Urologic Surgery and Andrology Mie University Graduate School of Medicine Tsu Mie Japan

2. Department of Urology Aichi Cancer Center Hospital Nagoya Aichi Japan

3. Department of Urology Suzuka General Hospital Suzuka Mie Japan

4. Department of Pathology and Molecular Diagnostics Aichi Cancer Center Hospital Nagoya Aichi Japan

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/iju5.12508

Reference20 articles.

1. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

2. Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies

3. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

4. Epidemiology, staging and management of prostate cancer;Barsouk A;Med. Sci.,2020

5. Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP